This is a preview of subscription content, log in via an institution to check access.
References
IMS Health. IMS MIDAS (2009).
Rice, L. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197, 1079–1081 (2008).
Projan, S. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427–430 (2003).
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: non-inferiority clinical trials. FDA website [online], (2010).
Extance, A. Biologics target bad bugs. Nature Rev. Drug Discov. 9, 177–178 (2010).
IMS Health. IMS LifeCycle (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Hamad, B. The antibiotics market. Nat Rev Drug Discov 9, 675–676 (2010). https://doi.org/10.1038/nrd3267
Issue Date:
DOI: https://doi.org/10.1038/nrd3267
- Springer Nature Limited
This article is cited by
-
Loss of allosteric regulation in α-isopropylmalate synthase identified as an antimicrobial resistance mechanism
npj Antimicrobials and Resistance (2023)
-
Non-antibiotic pharmaceuticals promote conjugative plasmid transfer at a community-wide level
Microbiome (2022)
-
Arcopilus eremanthusum sp. nov. as sources of antibacterial and antioxidant metabolites
Archives of Microbiology (2022)
-
Non-antibiotic pharmaceuticals promote the transmission of multidrug resistance plasmids through intra- and intergenera conjugation
The ISME Journal (2021)
-
QuEChERS Approach for the Analysis of Three Fluoroquinolone Antibiotics in Wastewater: Concentration Profiles and Ecological Risk in Two Nigerian Hospital Wastewater Treatment Plants
Archives of Environmental Contamination and Toxicology (2021)